Paul Corn

Chair

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (47)

Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.

Year:

2025

Year:

2025

Year:

2025

Therapeutic resistance in cancer significantly contributes to mortality, with many patients eventually experiencing recurrence after initial treatment responses. Recent studies have identified therapy-resistant large polyploid cancer cells in patient tissues, particularly in late-stage prostate cancer, linking them to advanced disease and relapse. Here, we analyzed bone marrow aspirates from 44 advanced prostate cancer patients and found the presence of circulating tumor cells with increased genomic content (CTC-IGC) was significantly associated with poorer progression-free survival. Single cell copy number profiling of CTC-IGC displayed clonal origins with typical CTCs, suggesting complete polyploidization. Induced polyploid cancer cells from PC3 and MDA-MB-231 cell lines treated with docetaxel or cisplatin were examined through single cell DNA sequencing, RNA sequencing, and protein immunofluorescence. Novel RNA and protein markers, including HOMER1, TNFRSF9, and LRP1, were identified as linked to chemotherapy resistance. These markers were also present in a subset of patient CTCs and are associated with recurrence in public gene expression data. This study highlights the prognostic significance of large polyploid tumor cells, their role in chemotherapy resistance, and the expression of markers tied to cancer relapse, offering new potential avenues for therapeutic development.

Year:

2025

Supplementary Table S13. Quantification of each protein-specific band normalized to vinculin (macrophage cells (RAW264.7) mono- or cocultured with RM-1-BM EV or SPOPmut models under treatment with OLA, Fig. 5E).

Year:

2025

Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR

Year:

2025

Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle

Year:

2025

Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.

Year:

2025

Supplementary Table S2. Listing of protein features differentially expressed in Dox-inducible SPOPmut (F102C and F133V) C4-2b prostate cancer cells compared to C4-2b vector control shown in Fig. 2A upper panel

Year:

2025

Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (31)

Ryan Park

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Chad Huff

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Timothy C. Thompson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Johannes Fahrmann

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Theocharis Panaretakis

Associate Professor

Karolinska Institutet

SWEDEN
View details

Louis Pisters

Professor of Urology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nora M. Navone

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Massimo Loda

Chair

Weill Cornell Medical College

UNITED STATES
View details

Sue-Hwa Lin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jody Vykoukal

Group Leader

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

W. Robert Lee

Professor

Duke University

UNITED STATES
View details

James P. Allison

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Susan Halabi

Duke University

UNITED STATES
View details

Paul Viscuse

Assistant Professor

University of Virginia

UNITED STATES
View details

Miao Zhang

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mark Titus

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sreyashi Basu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eric Konnick

Associate Professor

University of Washington

UNITED STATES
View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nathaniel Wilson

Assistant Professor of Hematology and Medical Oncology

Winship Cancer Institute of Emory University

UNITED STATES
View details

john Davis

Associate Professor

MD Anderson Cancer Center

UNITED STATES
View details

Jeremiah Sanders

Assistant Professor and Senior Associate Consultant

Mayo Clinic

UNITED STATES
View details

John Ward

Professor

MD Anderson Cancer Center

UNITED STATES
View details

Mohamed Kamal

Research Scientist

University of Southern California

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wenyi Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marites Melancon

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details